Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin

Annals of Surgical Oncology

Volumn 16, Issue 7, 2009, Pages 2065-2073

  De Jong, Gabie M ^a   Hendriks, Thijs ^a   Eek, Annemarie ^a   Oyen, Wim J G ^a   Heskamp, Sandra ^a   Bleichrodt, Robert P ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; INDIUM 111; INDIUM 111 MONOCLONAL ANTIBODY MG1; LUTETIUM 177; LUTETIUM 177 MONOCLONAL ANTIBODY MG1; LUTETIUM 177 MONOCLONAL ANTIBODY UPC 10; MONOCLONAL ANTIBODY; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; IN VIVO STUDY; INJECTION; INOCULATION; ISOTOPE LABELING; LAPAROTOMY; LIVER METASTASIS; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; POSTOPERATIVE PAIN; RADIOIMMUNOTHERAPY; RAT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS; MALE; RADIOIMMUNOTHERAPY; RATS; SURVIVAL ANALYSIS;

EID: 67649158712     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0477-6     Document Type: Article

References (30)

1. National Cancer Institute. http://www.cancer.gov/. Assessed 13 June 2007.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57(1):43-66.
3. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43.
4. Scheele J, Stangl R, tendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241-6.
5. Millikan KW, Staren ED, Doolas A. Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am. 1997;77(1):27-48.
6. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology. 2005;237(1):123-31.
7. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6): 352-8.
8. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008;(3):CD005390.
9. Behr TM, Salib AL, Liersch T, Behe M, Angerstein C, Blumenthal RD, et al. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res. 1999;5(10 suppl):3232s-42s.
10. Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res. 1994;54(1):142-51.
11. Koppe MJ, Soede AC, Pels W, Oyen WJ, Goldenberg DM, Bleichrodt RP, et al. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int J Cancer. 2003; 106(6):965-72.
12. Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJ, Bleichrodt RP. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol. 2007;14(11):3274-82.
13. Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: a review ''of mice and men''. Hybridoma. 1997; 16(1):101-7.
14. Zedeck MS. A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate. J Natl Cancer Inst. 1974;53:1419-21.
15. Koppe MJ, Hendriks T, Boerman OC, Oyen WJ, Bleichrodt RP. Radioimmunotherapy is an effective adjuvant treatment modality after cytoreductive surgery of peritoneal carcinomatosis of colonic origin. J Nucl Med. 2006;47(11):1867-74.
16. Hagenaars M, Koelemij R, Ensink NG, van Eendenburg JD, van Vlierberghe RL, Eggermont AM, et al. The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin Exp Metastasis. 2000;18(4):281-9.
17. Hagenaars M, Ensink NG, Basse PH, Hokland M, Nannmark U, Eggermont AM, et al. The microscopic anatomy of experimental rat CC531 colon tumor metastases: consequences for immunotherapy? Clin Exp Metastasis. 2000;18(2):189-96.
18. de Jong GM, Boerman OC, Heskamp S, Aarts F, Bleichrodt RP, Hendriks T. Radioimmunotherapy prevents local recurrence of colon cancer in rats. Br J Surg. 2008;96:314-21.
19. Lopes Cardozo AM, Gupta A, Koppe MJ, Meijer S, van Leeuwen PA, Beelen RJ, et al. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol. 2001;27(4): 359-63.
20. de Jong GM, Aarts F, Hendriks T, Boerman OC, Bleichrodt RP. Animal models for liver metastases of colorectal cancer: research review of preclinical studies in rodents. J Surg Res. 2008 (Epub ahead of print).
21. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39(1-2): 195-201.
22. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39(1-2):181-94.
23. Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, et al. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial. Anticancer Res. 1999;19(4A):2427-32.
24. Koppe MJ, Bleichrodt RP, Oyen WJ, Boerman OC. Radioimmunotherapy and colorectal cancer. Br J Surg. 2005;92(3):264-76.
25. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002;94(4 suppl):1373-81.
26. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50(3 suppl):814s-9s.
27. Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, Mala C, et al. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res. 2005;11(19 Pt 2):7178s-86s.
28. Aarts F, Koppe MJ, Hendriks T, van Eerd JE, Oyen WJ, Boerman OC, et al. Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2007;14(2):533-40.
29. Aarts F, Bleichrodt RP, de Man B, Lomme R, Boerman OC, Hendriks T. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann Surg Oncol. 2008;15(11): 3299-307.
30. Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, et al. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 2004;45(7): 1224-32.